GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ARCA Biopharma
ARCA Biopharma is a clinical-stage biotechnology company focused on genetically targeted therapies for cardiovascular diseases. Its stock price is highly volatile and depends almost entirely on the results of clinical trials.
Share prices of companies in the market segment - Heart
ARCA Biopharma is a biopharmaceutical company that uses genetic markers to develop targeted drugs for the treatment of cardiovascular diseases. We've categorized it as a "Heart" company, and the chart below shows how investors view personalized medicine approaches in cardiology.
Broad Market Index - GURU.Markets
ARCA Biopharma is a biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. As a component of the GURU.Markets index, it represents the personalized medicine sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ABIO - Daily change in the company's share price ARCA Biopharma
For ARCA Biopharma, Inc., a company developing drugs for the treatment of cardiovascular diseases, daily volatility reflects sensitivity to clinical trial data. This metric is key for assessing risks in biotech.
Daily change in the price of a set of shares in a market segment - Heart
ARCA Biopharma develops genetically targeted drugs for the treatment of cardiovascular diseases. This is a risky area of biotechnology. The chart below shows the high volatility typical of this sector, reflecting the stakes associated with ABIO's clinical trials.
Daily change in the price of a broad market stock, index - GURU.Markets
ARCA Biopharma is a biotech company specializing in the treatment of cardiovascular diseases. Given the prevalence of these diseases, its developments are attracting attention. Its shares are volatile and dependent on research progress, contributing to market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ARCA Biopharma
For ARCA Biopharma, Inc., the year-over-year trend is a story about developing genetically targeted drugs for the treatment of cardiovascular diseases. Its 12-month market capitalization is entirely dependent on clinical trial data. The success of its approach could be a breakthrough in personalized cardiology, but risks in biotech are high.
Annual dynamics of market capitalization of the market segment - Heart
As an early-stage biotech company, ARCA is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its heart disease drugs. Its stock price will reflect investors' speculative belief in its potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
ARCA Biopharma, a company developing genetically targeted drugs for the treatment of cardiovascular diseases, is an example of personalized medicine. Its annual market capitalization dynamics, compared to the market, depend entirely on the results of clinical trials. This is a high-risk bet on a scientific breakthrough.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ARCA Biopharma
ARCA Biopharma is a clinical-stage biopharmaceutical company focused on cardiovascular diseases. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its flagship programs are binary events.
Monthly dynamics of market capitalization of the market segment - Heart
ARCA Biopharma develops genetically targeted drugs for the treatment of cardiovascular diseases. This is an example of personalized medicine in cardiology. The chart below reflects the general sentiment in the heart disease treatment sector, where new approaches are in high demand.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
ARCA Biopharma is a clinical-stage biotech company focused on treating cardiovascular diseases. Its shares are a classic venture capital bet. Their performance is entirely dependent on the success or failure of clinical trials and has no correlation to broader market movements.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ARCA Biopharma
Shares of ARCA Biopharma, a clinical-stage company developing genetically targeted cardiac therapies, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials. The chart below illustrates how short-term scientific developments and investor expectations can cause sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Heart
ARCA Biopharma develops genetically targeted drugs for the treatment of cardiovascular diseases. This is a cutting-edge, yet risky, field. The chart clearly shows how much the company's stock price is dependent on clinical trial results rather than general trends in the pharmaceutical industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
ARCA Biopharma is a biotech company. This chart shows how its weekly performance, like that of other biotechs, is detached from the market. Share movements are driven by news about clinical trials and regulatory decisions, not macroeconomic data.
Market capitalization of the company, segment and market as a whole
ABIO - Market capitalization of the company ARCA Biopharma
The ARCA Biopharma, Inc. valuation chart represents its genetically targeted approach to developing cardiovascular drugs. This clinical-stage biotech company's market cap depends on the success of its research. The dynamics illustrate the risks and promises associated with personalized medicine.
ABIO - Share of the company's market capitalization ARCA Biopharma within the market segment - Heart
ARCA Biopharma's stake in the cardiology sector is a bet on personalized medicine. Its market share is based on the potential of its drug candidate for the treatment of atrial fibrillation in patients with a specific genetic profile. This represents the future of targeted therapy in cardiology.
Market capitalization of the market segment - Heart
This chart shows the total market capitalization of biotech companies developing drugs to treat cardiovascular diseases. ARCA Biopharma is one such player. The dynamics in the chart reflect the high volatility and risks associated with clinical trials in this complex field.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph visualizes hope for patients with cardiovascular disease who have a specific genetic predisposition. ARCA Biopharma's market capitalization is a bet on its personalized approach to treatment. The line shows how highly specialized science is vying for its share of global cardiology.
Book value capitalization of the company, segment and market as a whole
ABIO - Book value capitalization of the company ARCA Biopharma
ARCA Biopharma's clinical-stage book value is determined by its scientific potential. The chart below reflects the financial valuation of its intellectual property for cardiovascular drugs. The dynamics demonstrate how the company is investing in the development of its most important asset—science.
ABIO - Share of the company's book capitalization ARCA Biopharma within the market segment - Heart
For ARCA Biopharma, a clinical-stage biopharmaceutical company, its tangible assets are limited to laboratories. The chart shows its modest share of physical infrastructure, emphasizing that its value at this stage lies in research data, not manufacturing facilities.
Market segment balance sheet capitalization - Heart
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. ARCA Biopharma, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
ARCA Biopharma develops genetically targeted drugs for the treatment of cardiovascular diseases. The company's assets are not hospitals, but a patent portfolio and clinical trial data. The chart shows the financial resources devoted to the creation of "personalized" heart medications.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ARCA Biopharma
ARCA Biopharma is a biopharmaceutical company developing drugs for the treatment of cardiovascular diseases. Its market value is determined by its scientific developments and its potential to offer new solutions in this important area of medicine.
Market to book capitalization ratio in a market segment - Heart
ARCA Biopharma, Inc. is a biotech company developing drugs to treat cardiovascular diseases. Its value depends on the success of its clinical programs. This chart clearly shows how its market valuation is a bet on future drugs and is significantly out of touch with its current assets.
Market to book capitalization ratio for the market as a whole
ARCA Biopharma develops genetically targeted drugs for the treatment of cardiovascular diseases. The company's market valuation, shown in this chart, is based on the potential of its scientific developments. The dynamics reflect investor expectations for clinical trial results.
Debts of the company, segment and market as a whole
ABIO - Company debts ARCA Biopharma
ARCA Biopharma, a clinical-stage biotech company, is using raised capital to develop its genetically targeted drugs for cardiovascular disease. This chart shows how the company spends investor funds on clinical trials, a long-term and risky process.
Market segment debts - Heart
ARCA Biopharma is a biotech company developing genetically targeted drugs for the treatment of cardiovascular diseases. This chart shows how its debt policy reflects the high risk and capital intensity of its research, which is primarily funded by equity while its drugs are in the clinical stage.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ARCA Biopharma
Accolade provides personalized healthcare services and navigation for employees of large companies. It is a technology and services platform. This chart shows how the company is using capital to expand its customer base and develop its technology platform in the competitive digital health market.
Market segment debt to market segment book capitalization - Heart
ARCA Biopharma is a biotech company developing genetically targeted drugs for the treatment of cardiovascular diseases. This chart compares its debt load to the overall market capitalization of the pharmaceutical sector. It shows how the company finances its highly specialized research at the clinical stage.
Debt to book value of all companies in the market
ARCA Biopharma is a biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. Personalized medicine is the future, but R&D in this area is expensive. This chart of total market debt helps understand the environment in which ARCA is raising capital for its innovative clinical research.
P/E of the company, segment and market as a whole
P/E - ARCA Biopharma
For ARCA Biopharma, a clinical-stage biotech, the P/E ratio is irrelevant. The company has no profit, and its valuation on this chart is arbitrary. Its true value is determined by the potential of its scientific developments in treating cardiovascular diseases.
P/E of the market segment - Heart
ARCA Biopharma is a biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. Their approach involves selecting therapies based on a patient's genetic profile. This chart shows the average valuation for the cardiology sector, reflecting investor expectations for personalized medicine in the treatment of heart disease.
P/E of the market as a whole
ARCA Biopharma is a biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. The company's approach is based on tailoring therapy based on a patient's genetic profile. This risk appetite chart helps understand how investors view the personalized medicine sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ARCA Biopharma
ARCA Biopharma is a biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. This chart reflects future revenue expectations, which depend on the success of clinical trials and the potential of personalized medicine in cardiology.
%20P%2FE%20ARCA%20Biopharma&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ARCA-Biopharma&v=1772693515458 "Chart of the company's future (projected) P/E ARCA Biopharma")
Future (projected) P/E of the market segment - Heart
ARCA Biopharma is a biotech company developing genetically targeted drugs for the treatment of cardiovascular diseases. This chart reflects investor expectations for its scientific platform. It compares the market valuation of ARCA's potential with that of other cardiac biopharmaceutical companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Heart&v=1772693515489 "Future (projected) P/E graph of the market segment - Heart")
Future (projected) P/E of the market as a whole
ARCA Biopharma is a biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. Its future depends on successful clinical trials. The overall market optimism reflected in this chart is important for attracting the capital needed to conduct lengthy and expensive research in this competitive field.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772693515512 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ARCA Biopharma
ARCA Biopharma is a clinical-stage biopharmaceutical company specializing in the development of genetically targeted drugs for the treatment of cardiovascular diseases. Its financial performance is driven by R&D expenses. This chart illustrates the significant investment in science required for personalized medicine.
Profit of companies in the market segment - Heart
ARCA Biopharma is a biopharmaceutical company developing genetically targeted treatments for cardiovascular diseases. This graph, showing overall sector profitability, highlights the potential of personalized medicine. ARCA's success in developing treatments for patients with specific genetic markers could radically change the standard of care.
Overall market profit
ARCA Biopharma is a biotechnology company developing genetically targeted drugs for the treatment of cardiovascular diseases. Its approach is based on personalized medicine. The company's success depends entirely on the results of clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ARCA Biopharma
ARCA Biopharma is a biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. Future profit projections are speculative and depend entirely on the success of clinical trials.
%20profit%20of%20the%20company%20ARCA%20Biopharma&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ARCA-Biopharma&v=1772693515621 "Graph of future (projected) profit of the company ARCA Biopharma")
Future (predicted) profit of companies in the market segment - Heart
ARCA Biopharma is a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases. This chart shows overall profitability forecasts for the cardiology sector. It helps understand how the company's approach to personalized medicine in this field compares to overall financial expectations for innovations in heart disease treatment.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Heart&v=1772693515625 "Graph of future (predicted) profits of companies in a market segment - Heart")
Future (predicted) profit of the market as a whole
ARCA Biopharma is a biotech company developing genetically targeted drugs for the treatment of cardiovascular diseases. Its success depends on the results of clinical trials. This chart is important because it reflects investors' risk appetite. During periods of market growth, ARCA Biopharma finds it easier to raise capital to fund its research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772693515628 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ARCA Biopharma
ARCA Biopharma is a clinical-stage biotech company specializing in the development of genetically targeted drugs for the treatment of cardiovascular diseases. This chart, plotting its market capitalization against its missing revenue, reflects its scientific potential and demonstrates investors' faith in its personalized approach to medicine.
P/S market segment - Heart
ARCA Biopharma is a biopharmaceutical company that uses a genetic approach to develop targeted drugs for the treatment of cardiovascular diseases. The company is committed to personalized medicine. This chart shows how investors value the cardiology sector's revenue, demonstrating the level of expectations for ARCA's scientific approach and clinical development.
P/S of the market as a whole
ARCA Biopharma is a biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. Its valuation is dependent on the success of clinical trials. This chart, showing the average valuation, demonstrates how much biotech companies' valuations depend on future potential.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ARCA Biopharma
ARCA Biopharma is a biotechnology company developing genetically targeted drugs for the treatment of cardiovascular diseases. This chart shows the market's assessment of its potential future revenue, reflecting investor confidence in the success of its clinical programs and the commercial potential of personalized medicine.
%20P%2FS%20ARCA%20Biopharma&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ARCA-Biopharma&v=1772693515690 "The graph of the company's future (projected) P/S ARCA Biopharma")
Future (projected) P/S of the market segment - Heart
ARCA Biopharma is a clinical-stage biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. The chart shows the average estimated future sales in the cardiology sector. It helps understand how investors view ARCA's scientific approach and its chances of success in this complex and capital-intensive field.
%20P%2FS%20market%20segment%20graph%20-%20Heart&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Heart&v=1772693515700 "Future (projected) P/S market segment graph - Heart")
Future (projected) P/S of the market as a whole
ARCA Biopharma (ABIO) is a biotech company developing genetically targeted drugs for the treatment of cardiovascular diseases. Their future depends solely on the success of clinical trials. This graph of general economic expectations has no bearing on their scientific developments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772693515714 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ARCA Biopharma
ARCA Biopharma is a clinical-stage biotech company specializing in genetically targeted drugs for the treatment of cardiovascular diseases. It has no sales revenue. Its financial history is based on investments in research, and the graph reflects future revenue from licensing or partnerships.
Sales of companies in the market segment - Heart
ARCA Biopharma is a clinical-stage biopharmaceutical company focused on developing genetically targeted therapies for the treatment of cardiovascular diseases. It currently has no sales revenue. Its future revenue depends on the success of its innovative approach to personalized cardiology.
Overall market sales
ARCA Biopharma, Inc. is a biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. Its success depends on the results of clinical trials. Demand for drugs for life-threatening conditions is inelastic, but the overall economic situation, shown in this chart, affects the availability of capital for R&D.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ARCA Biopharma
ARCA Biopharma is a biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. Future revenue is dependent on the success of clinical trials. This chart reflects analysts' long-term expectations for its research and development pipeline.
%20sales%20of%20the%20company%20ARCA%20Biopharma&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ARCA-Biopharma&v=1772693515777 "Schedule of future (projected) sales of the company ARCA Biopharma")
Future (projected) sales of companies in the market segment - Heart
ARCA Biopharma is a biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. This chart shows the outlook for the cardiology sector. It reflects the need for personalized treatment approaches, which is the basis for ARCA's innovative developments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Heart&v=1772693515794 "Schedule of future (projected) sales of companies in the market segment - Heart")
Future (projected) sales of the market as a whole
This chart reflects the investment climate in biotech, which is critical for ARCA Biopharma. The company develops genetically targeted drugs for the treatment of cardiovascular diseases. Funding for its research depends on capital inflows into the sector, which increase with economic growth.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772693515797 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ARCA Biopharma
ARCA Biopharma is a clinical-stage biotechnology company developing genetically targeted drugs for the treatment of cardiovascular diseases. This chart reflects its investment in research. Future profitability is entirely dependent on the success of clinical trials and the commercialization of its personalized drugs.
Market segment marginality - Heart
ARCA Biopharma is a biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. Profitability depends on the success of its personalized approach in clinical trials. This chart shows the average profitability in the pharmaceutical industry, helping to assess the potential of its innovative strategy.
Market marginality as a whole
ARCA Biopharma is a biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. As a research-stage company, it relies on funding and the success of clinical trials. This chart reflects the overall risk appetite of investors, which determines the availability of capital for long-term biotech projects.
Employees in the company, segment and market as a whole
Number of employees in the company ARCA Biopharma
ARCA Biopharma is a biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. This graph shows a compact scientific team. A small staff is typical for clinical-stage companies focused on research. Growth will indicate progress in clinical programs.
Share of the company's employees ARCA Biopharma within the market segment - Heart
ARCA Biopharma develops genetically targeted drugs for the treatment of cardiovascular diseases. This chart shows the company's share of the total number of scientists working in the field of cardiac pharmacogenetics. This reflects its innovative approach to creating personalized medications for the heart.
Number of employees in the market segment - Heart
ARCA Biopharma is a biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. This chart, showing employment in the cardiac research sector, is important. The growing number of genetic scientists in this field indicates the advancement of personalized medicine and the search for new approaches to treating heart disease.
Number of employees in the market as a whole
ARCA Biopharma develops genetically targeted drugs for the treatment of cardiovascular diseases. The success of such innovations depends on funding. This overall employment chart reflects the health of the economy, which allows investors and governments to invest in personalized medicine, which has the potential to radically change treatment approaches.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ARCA Biopharma (ABIO)
ARCA Biopharma (ABIO) is a biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. This chart demonstrates a high valuation of its "intellectual capital." The company's market value is derived from its scientific platform and patents, not its staff. The market evaluates the potential of its drugs.
%20of%20the%20company%20ARCA%20Biopharma%20(ABIO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ARCA-Biopharma-ABIO&v=1772693515987 "Chart of market capitalization per employee (in thousands of dollars) of the company ARCA Biopharma (ABIO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Heart
ARCA Biopharma is a biotech company developing genetically targeted drugs for the treatment of cardiovascular diseases. Its value lies in its scientific research and patents. This chart illustrates the enormous potential value the market places on the work of a small team of scientists, which is typical for research-intensive companies in the clinical stage.
%20by%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Heart&v=1772693516001 "Market capitalization per employee (in thousands of dollars) by market segment - Heart")
Market capitalization per employee (in thousands of dollars) for the overall market
ARCA Biopharma is a biotech company developing genetically targeted drugs for the treatment of cardiovascular diseases. Its market capitalization is based on its scientific potential. This chart shows the high valuation per employee, typical for biotech, where investors are betting on the future success of a small scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772693516008 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ARCA Biopharma (ABIO)
ARCA Biopharma is a clinical-stage biotech company focused on developing genetically targeted drugs for the treatment of cardiovascular diseases. This is pure R&D. This chart shows the company's capital burn rate: how much the company spends (negative profit) on each scientist conducting clinical trials.
%20Chart%20ARCA%20Biopharma%20(ABIO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ARCA-Biopharma-ABIO&v=1772693516019 "Company Profit Per Employee (in thousands of dollars) Chart ARCA Biopharma (ABIO)")
Profit per employee (in thousands of dollars) in the market segment - Heart
ARCA Biopharma is a biopharmaceutical company specializing in the development of genetically targeted drugs for the treatment of cardiovascular diseases. While in clinical development, the company may not be profitable. This chart helps evaluate the efficiency of investment capital on the path to potential commercialization.
%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Heart&v=1772693516032 "Chart of profit per employee (in thousands of dollars) in the market segment - Heart")
Profit per employee (in thousands of dollars) for the market as a whole
ARCA Biopharma (ABIO) is a clinical-stage biopharmaceutical company developing genetically targeted therapies for the treatment of cardiovascular diseases. It is an R&D company with no profit. This metric is negative and reflects the "cost" of a single scientist working in the complex field of cardiology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772693516049 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ARCA Biopharma (ABIO)
ARCA Biopharma is a biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases. Revenue is minimal during clinical trials. This graph is important as a starting point for assessing the potential success of their innovative approaches.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ARCA-Biopharma-ABIO&v=1772693516074 "Sales chart per company employee ARCA Biopharma (ABIO)")
Sales per employee in the market segment - Heart
ARCA Biopharma is a clinical-stage biotech company developing targeted drugs for the treatment of cardiovascular diseases (such as atrial fibrillation). This is an R&D business. This chart shows that the company has no commercial revenue. The productivity of their scientific team lies in advancing candidates through clinical trials.
Sales per employee for the market as a whole
ProAssurance (PRA) is a specialized insurance company, a leader in malpractice insurance, particularly for physicians and hospitals. It's a niche insurance business. This chart shows underwriting efficiency. The insurer's revenue comes from collected premiums. Success here depends on the ability of a small team of underwriters and actuaries to accurately assess risk and price policies.
Short shares by company, segment and market as a whole
Shares shorted by company ARCA Biopharma (ABIO)
ARCA Biopharma (ABIO) is a clinical-stage biotech company focused on cardiovascular diseases. This chart tracks short positions. Shorting is a direct bet on clinical trial failure.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ARCA-Biopharma-ABIO&v=1772693516104 "Short Shares Chart for the Company ARCA Biopharma (ABIO)")
Shares shorted by market segment - Heart
ARCA Biopharma (ABIO) is a biotech company developing targeted drugs for the treatment of cardiovascular diseases. The chart below represents a general short position in the biotech sector, demonstrating investor skepticism regarding the success of risky clinical trials.
Shares shorted by the overall market
ARCA Biopharma (ABIO) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing ABIO won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ARCA Biopharma (ABIO)
This chart for ARCA Biopharma is a story of "second chances" in biotech. The company suffered a setback with its heart drug and is now trying to find new applications (COVID, cancer). "Overheating" (above 70) occurs with new program announcements. A history of failures and a lack of focus keep the stock deeply "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ARCA-Biopharma-ABIO&v=1772693516122 "RSI 14 indicator chart for the company's stock ARCA Biopharma (ABIO)")
RSI 14 Market Segment - Heart
ARCA Biopharma is a biotech company focused on the heart. Their specialty is genetically targeted therapy for cardiovascular diseases (atrial fibrillation). The Heart (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the entire segment. It helps us understand: is ABIO's growth driven by their R&D, or is the entire biotech sector overheated?
RSI 14 for the overall market
ARCA Biopharma (ABIO) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ABIO (ARCA Biopharma)
ARCA Biopharma (ABIO) is a biotech company developing genetically targeted drugs for the treatment of cardiovascular diseases. This chart shows the average target price. It reflects analysts' speculative assessment of its scientific platform and the likelihood of success in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ABIO-ARCA-Biopharma&v=1772693516143 "A chart showing analyst consensus forecasts for the expected stock price. ABIO (ARCA Biopharma)")
The difference between the consensus estimate and the actual stock price ABIO (ARCA Biopharma)
ARCA Biopharma (ABIO) is a biotech company developing genetically targeted drugs for the treatment of cardiovascular diseases. This chart shows how far the current share price differs from its "fair" value. It reflects analysts' views on their R&D portfolio and the chances of success in precision cardiology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ABIO-ARCA-Biopharma&v=1772693516150 "A chart showing the difference between the consensus forecast and the actual stock price. ABIO (ARCA Biopharma)")
Analyst consensus forecast for stock prices by market segment - Heart
ARCA Biopharma is a clinical-stage biotech company developing genetically targeted drugs for the treatment of cardiovascular diseases. This chart shows general expectations for the cardiology sector, reflecting experts' belief in personalized medicine for heart treatment.
Analysts' consensus forecast for the overall market share price
ARCA Biopharma (ABIO) is a clinical-stage biopharmaceutical company developing genetically targeted drugs for the treatment of cardiovascular diseases (atrial fibrillation). This chart shows the overall risk appetite, reflecting the market's willingness to fund R&D projects in one of the most complex areas of medicine.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ARCA Biopharma
ARCA Biopharma is a biotech R&D company focused on genetically targeted cardiac therapies (atrial fibrillation, heart failure). This is precision medicine for cardiology. This chart is a pure indicator of faith in their R&D. It doesn't reflect revenue, but rather a speculative assessment of their (very risky) pipeline and their clinical trial data.
AKIMA Market Segment Index - Heart
ARCA Biopharma is a company developing genetically targeted treatments for cardiovascular diseases. They select medications based on a patient's DNA. They are the future of cardiology. This chart compares their composite index with the sector, showing how their gene-based approach to cardiac treatment compares to others.
The AKIM Index for the overall market
ARCA Biopharma is a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases (atrial fibrillation). This chart, reflecting the market average, provides a macro backdrop. It helps assess how ABIO, which is exploring strategic alternatives, stacks up against overall economic trends.
